| ||
|
jueves, 17 de mayo de 2012
Duración optima de la anticoagulación en pacientes con tromboembolismo venoso
Novedades en la Ortografìa
Reglas de Ortografía | Boletín n.º 41 | |
http://www.reglasdeortografia.com | Morón de la Frontera, 17 de mayo de 2012 |
Examen polémico
|
En reglasdeortografia.com tienes la posibilidad de hacer la prueba: Si bien, el planteamiento es distinto, toda vez, que el enmarque es totalmente educativo y podrás realizar el ejercicio las veces que quieras con la particularidad, eso sí, de que no verás ninguna pista de las palabras con errores a la hora de comprobar el ejercicio corregido y, en su lugar, las respuestas solo señalarán en rojo las frases que contengan palabras mal escritas.
¿Aprobarías el examen en el que suspendieron 138 policías grancanarios? Sería bueno que conocieras tu nivel:
El hombre séptico... sin ninguna duda
See Inside
http://www.scientificamerican.com/article.cfm?id=ultimate-social-network-bacteria-protects-health
Bacteria in Our Bodies Protect Our Health [Preview]
Researchers who study the friendly bacteria that live inside all of us are starting to sort out who is in charge—microbes or people?
- Share
Image: Bryan Christie
In Brief
- Bacterial cells in the body outnumber human cells by a factor of 10 to 1. Yet only recently have researchers begun to elucidate the beneficial roles these microbes play in fostering health.
- Some of these bacteria possess genes that encode for beneficial compounds that the body cannot make on its own. Other bacteria seem to train the body not to overreact to outside threats.
- Advances in computing and gene sequencing are allowing investigators to create a detailed catalogue of all the bacterial genes that make up this so-called microbiome.
- Unfortunately, the inadvertent destruction of beneficial microbes by the use of antibiotics, among other things, may be leading to an increase in autoimmune disorders and obesity.
Biologists once thought that human beings were physiological islands, entirely capable of regulating their own internal workings. Our bodies made all the enzymes needed for breaking down food and using its nutrients to power and repair our tissues and organs. Signals from our own tissues dictated body states such as hunger or satiety. The specialized cells of our immune system taught themselves how to recognize and attack dangerous microbes—pathogens—while at the same time sparing our own tissues.
Over the past 10 years or so, however, researchers have demonstrated that the human body is not such a neatly self-sufficient island after all. It is more like a complex ecosystem—a social network—containing trillions of bacteria and other microorganisms that inhabit our skin, genital areas, mouth and especially intestines. In fact, most of the cells in the human body are not human at all. Bacterial cells in the human body outnumber human cells 10 to one. Moreover, this mixed community of microbial cells and the genes they contain, collectively known as the microbiome, does not threaten us but offers vital help with basic physiological processes—from digestion to growth to self-defense.
http://www.scientificamerican.com/article.cfm?id=microbiome-graphic-explore-human-microbiome
Explore the Human Microbiome [Interactive]
Learn about the bacteria, fungi and other micro-organisms that maintain human health.
By Christine Gorman | May 15, 2012 | 6
- Share
The body contains 10 times more bacteria, fungi and other micro-organisms than human cells. Most of these species are harmless—although they can still cause illness if they wind up in the wrong place. In addition, researchers are beginning to learn exactly how some microbial species in the body help digestion and contribute to regulation of appetite and the immune system.
Illustration by Bryan Christie
See Inside
Swapping Germs: Should Fecal Transplants Become Routine for Debilitating Diarrhea?
A potentially beneficial but unusual treatment for serious intestinal ailments may fall victim to regulatory difficulties
By Maryn McKenna | December 6, 2011 | 31
STRAIGHT POOP: Bacteria shed from the intestine (some of which are colored purple here) make up much of human feces.Image: Tony Brain/Photo Researchers, Inc.
Marion Browning of North Providence, R.I., was at her wit’s end. The 79-year-old retired nurse had suffered from chronic diarrhea for almost a year. It began after doctors prescribed antibiotics to treat her diverticulitis, a painful infection of small pouches in the wall of the colon. The regimen also killed friendly bacteria that lived in Browning’s intestines, allowing a toxin-producing organism known as Clostridium difficile to take over and begin eating away at the entire lining of her gut.
For months Browning was in and out of her doctor’s office, getting big-gun antibiotics to suppress the C. difficile infection. Each time a course of treatment ended she would feel better for a while. But her strain of C. difficile was stubborn: a few of the destructive bacteria always survived. Within a few days they would begin multiplying, and the racking diarrhea would recur. After four rounds of antibiotics, her gastroenterologist told her that he had done all he could think of. He recommended that she see Colleen Kelly, a clinical faculty member at Brown University’s medical school, who was trying something new.
Kelly proposed a treatment that sounded both logical and strangely unmedical. Normally, she told Browning, the friendly bacteria that reside in the human intestine maintain a seesawing balance that keeps pathogenic bacteria in check. That equilibrium can be temporarily disrupted—as with standard antibiotic treatment—but it nearly always returns to stability. Browning’s own bacterial community had lost that ability, probably for good. Still, there was a way to restore normality, Kelly said. She could replace Browning’s bacteria completely, by inserting into her colon a diluted sample of stool from someone whose intestinal health was good. If the good bacteria in the donated stool took hold and recolonized her intestine, the C. difficile would be crowded out, and she would be cured.
Browning had never heard of such a procedure—variously called fecal transplant, fecal bacteriotherapy or fecal flora reconstitution—but she was ready to try anything. Kelly asked her to recruit a healthy donor. Browning chose her 49-year-old son. In the fall of 2009 Browning performed the bowel-cleansing routine that precedes a colonoscopy, while her son took an overnight laxative. Kelly diluted the donation, then used colonoscopy instruments to squirt the solution high up in Browning’s large intestine. The diarrhea resolved in two days and has never recurred.
“I can’t understand why more doctors aren’t doing this,” says Browning, now 80. Yet a complex combination of federal regulations and research rules—along with just plain squeamishness—could keep the procedure from helping potentially thousands of people who might benefit.
A Growing Threat
Browning is not alone in being a success story. In medical journals, about a dozen clinicians in the U.S., Europe and Australia have described performing fecal transplants on about 300 C. difficile patients so far. More than 90 percent of those patients recovered completely, an unheard-of proportion. “There is no drug, for anything, that gets to 95 percent,” Kelly says. Plus, “it is cheap and it is safe,” says Lawrence Brandt, a professor of medicine and surgery at the Albert Einstein College of Medicine, who has been performing the procedure since 1999.
Browning is not alone in being a success story. In medical journals, about a dozen clinicians in the U.S., Europe and Australia have described performing fecal transplants on about 300 C. difficile patients so far. More than 90 percent of those patients recovered completely, an unheard-of proportion. “There is no drug, for anything, that gets to 95 percent,” Kelly says. Plus, “it is cheap and it is safe,” says Lawrence Brandt, a professor of medicine and surgery at the Albert Einstein College of Medicine, who has been performing the procedure since 1999.
So far, though, fecal transplants remain a niche therapy, practiced only by gastroenterologists who work for broad-minded institutions and who have overcome the ick factor. To become widely accepted, recommended by professional societies and reimbursed by insurers, the transplants will need to be rigorously studied in a randomized clinical trial, in which people taking a treatment are assessed alongside people who are not. Kelly and several others have drafted a trial design to submit to the National Institutes of Health for grant funding. Yet an unexpected obstacle stands in their way: before the NIH approves any trial, the substance being studied must be granted “investigational” status by the Food and Drug Administration. The main categories under which the FDA considers things to be investigated are drugs, devices, and biological products such as vaccines and tissues. Feces simply do not fit into any of those categories.
The physicians performing the transplants decry the regulatory bottleneck because new treatments for C. difficile infection are critically needed. C. diff, to use the common medical shorthand, has risen in the past 30 years from a recognized but tolerated consequence of antibiotic treatment to a serious health threat. Since 2000, when a virulent new strain emerged, cases have become much more common, occurring not only in the elderly but in children, pregnant women and people with no obvious health risks. One study estimated that the number of hospitalized adults withC. diff more than doubled from about 134,000 patients in 2000 to 291,000 patients in 2005. A second study showed that the overall death rate from C. diff had jumped fourfold, from 5.7 deaths per million in the general population in 1999 to 23.7 deaths per million in 2004.
C. diff has also become harder to cure. Thanks to increasing antibiotic resistance, standard treatment now relies on two drugs: metronidazole (Flagyl) and vancomycin. Both medications are so-called broad-spectrum antibiotics, meaning that they work against a wide variety of bacteria. Thus, when they are given to kill C. diff infection, they kill most of the gut’s friendly bacteria as well. The living space that those bacteria once occupied then becomes available for any C. diff organisms that survive the drugs’ attack. As a result, roughly 20 percent of patients who have had one episode of C. diffinfection will have a recurrence; 40 percent of those with one recurrence will have another; and 60 percent of those who experience a second bout are likely to suffer several more. Some victims with no other options must have their colon removed. (A new drug, fidaxomicin, which was approved for C. diff infection by the FDA in late May, may lead to fewer relapses because it is a narrow-spectrum antibiotic.)
A Simple Procedure
The details of how the transplantation of microbes eliminates C. diff infection have not been well studied, but Alex Khoruts, a gastroenterologist and immunologist at the University of Minnesota who has performed two dozen fecal transplants over the past two years, has demonstrated that the transplanted bacteria do take over the gut, replacing the absent friendly bacteria and outcompeting C. diff. In 2010 he analyzed the genetic makeup of the gut flora of a 61-year-old woman so disabled by recurrentC. diff that she was wearing diapers and was confined to a wheelchair. His results showed that before the procedure, in which the woman received a fecal sample from her husband, she harbored none of the bacteria whose presence would signal a healthy intestinal environment. After the transplant—and her complete recovery—the bacterial contents of her gut were not only normal but were identical to that of her husband.
The details of how the transplantation of microbes eliminates C. diff infection have not been well studied, but Alex Khoruts, a gastroenterologist and immunologist at the University of Minnesota who has performed two dozen fecal transplants over the past two years, has demonstrated that the transplanted bacteria do take over the gut, replacing the absent friendly bacteria and outcompeting C. diff. In 2010 he analyzed the genetic makeup of the gut flora of a 61-year-old woman so disabled by recurrentC. diff that she was wearing diapers and was confined to a wheelchair. His results showed that before the procedure, in which the woman received a fecal sample from her husband, she harbored none of the bacteria whose presence would signal a healthy intestinal environment. After the transplant—and her complete recovery—the bacterial contents of her gut were not only normal but were identical to that of her husband.
Most clinicians who perform fecal transplants ask their patients to find their own donors and prefer that they be a child, sibling, parent or spouse. “For me, it’s aesthetic,” says Christina Surawicz, a professor of medicine at the University of Washington, who has done transplants on two dozen patients and published an account of the first 19. “There’s something very intimate about putting someone else’s stool in your colon, and you are already intimate with a spouse.”
To ensure safety, the physicians performing the procedure require that donors have no digestive diseases and put them through the same level of screening that blood donation would require. That process imposes a cost in time and logistics because standard rules for medical confidentiality require a donor to be interviewed separately from the potential recipient. It also carries inherent financial penalties. The donor’s lab work most likely will not be covered by insurance; the transplant procedure may or may not be covered by the patient’s insurance.
Proponents have come up with work-arounds for those possible barriers. Khoruts no longer uses related donors—which requires finding a different individual for every case—but instead has recruited a cadre of “universal donors” from among local health care workers. (He has seen no change in how often the transplants “take.”) Last year Michael Silverman of the University of Toronto boldly proposed a yet more streamlined solution: having patients perform the transplants at home with a drugstore enema kit. A drawback, he cautioned in Clinical Gastroenterology and Hepatology, is that too much of the stool solution might leak out for the transplant to take. Nevertheless, seven patients with recurrent C. diff have safely performed the home version, he wrote, with a 100 percent recovery rate.
Next Steps
Even without large-scale rigorous investigations of fecal transplants, the medical community appears to be coming around to the practice. The Journal of Clinical Gastroenterology editorialized in September 2010 that “it is clear from all of these reports that fecal bacteriotherapy using donor stool has arrived as a successful therapy.” Albert Einstein’s Brandt recently suggested in the same journal that fecal transplants should be the first treatment tried for serious C. diff infection rather than a last resort. Increasing research interest in the influence of gut flora on the rest of the body—and on conditions as varied as obesity, anxiety and depression—will likely bring pressure for transplants to be adopted more widely.
Even without large-scale rigorous investigations of fecal transplants, the medical community appears to be coming around to the practice. The Journal of Clinical Gastroenterology editorialized in September 2010 that “it is clear from all of these reports that fecal bacteriotherapy using donor stool has arrived as a successful therapy.” Albert Einstein’s Brandt recently suggested in the same journal that fecal transplants should be the first treatment tried for serious C. diff infection rather than a last resort. Increasing research interest in the influence of gut flora on the rest of the body—and on conditions as varied as obesity, anxiety and depression—will likely bring pressure for transplants to be adopted more widely.
Currently three clinical trials of fecal transplants have begun in Canada. In the U.S., however, the research logjam persists. An FDA spokesperson said in an interview that there is no way to determine how the agency might rule on an investigational application until the application is brought. That tosses the initiative back to Kelly and her collaborators, who include Khoruts and Brandt. They hope to file with the FDA before much longer, but Kelly admits to being apprehensive over the possible outcome.
“We hope they will not ask things that we cannot answer,” she says. Medical centers need to be able to study the procedure, Kelly argues, “because people are trying it on their own.”
ABOUT THE AUTHOR(S)
Maryn McKenna is a journalist, a blogger and author of two books about public health. She writes about infectious diseases, global health and food policy.
Valencia acogió el 30 Congreso de la Asociación Española de Artroscopia
Valencia acogió el 30 Congreso de la Asociación Española de Artroscopia.
- Por Noticias Medicina
- Publicada: 14/05/2012
- Noticias Mayo 2012 , Noticias de Congresos Medicina ,Noticias de Traumatologia y Cirugia Ortopedica
Valencia acogió el 30 Congreso de la Asociación Española de Artroscopia.
|
Del 9 al 11 de mayo en el Palacio de Congresos.
- Prestigiosos cirujanos artroscopistas internacionales realizaron cinco cirugías en directo desde los quirófanos del Centro de Rehabilitación de Levante
Valencia, mayo de 2012.- Desde el pasado miércoles, día 9, y hasta el viernes 11, Valencia recibió a más de 600 especialistas en la patología articular artroscópica, con la participación de 150 ponentes.
Expertos cirujanos, tanto de España como de la Unión Europea y América se reunieron hasta el pasado viernes, en el Palacio de Congresos de Valencia, para abordar e intercambiar las técnicas más novedosas de la cirugía atroscópica de distintas articulaciones del cuerpo humano.
Si bien se abordó la cirugía artroscópica más frecuente y evolucionada, la de la rodilla y hombro, también, y aquí radica la novedad del Congreso, se ha hecho hincapié en las nuevas técnicas artroscópicas de otras articulaciones como cadera, codo, muñeca, mano y tobillo.
El presidente del Comité Organizador del 30 Congreso de Artroscopia, el Dr. Eduardo Sánchez Alepuz, médico cirujano de Unión de Mutuas, ha manifestado que “la cirugía artroscópica está desbancando a la cirugía convencional en la mayoría de las lesiones del aparato locomotor tanto de grandes como de pequeñas articulaciones, ofreciendo grandes beneficios para el paciente y rentabilidad económica para la sociedad y las instituciones sanitarias”.
Google presenta un nuevo modo de búsqueda inteligente
|
|
Ictericia Neonatal
Estimado Pediatra te invito al Seminario de Pediatría, Cirugía Pediátrica y Lactancia Materna. Programa 2012, el día 23 de mayo las 21hrs (Centro, México DF, Guadalajara y Lima Perú) a la Conferencia: “Ictericia Neonatal” por el “Dr. Moisés Quiles Corona ” Pediatra Neonatólogo de la Cd de Guadalajara Jal. La sesión inicia puntualmente las 21 hrs.
Para entrar a la Sala de Conferencia:
1.- hacer click en la siguiente liga, o cópiala y escríbela en tu buscador
2.- “Entra como Invitado” Escribes tu nombre y apellido en el espacio en blanco
3.- Hacer click en el espacio que dice “Entrar en la Sala”
5.- A disfrutar la conferencia
6.- Recomendamos que dejes tu Nombre Completo, Correo electrónico y que participes.
Henrys
Dr. Enrique Mendoza López
Webmaster: CONAPEME
Coordinador Nacional: Seminario Ciberpeds-Conapeme
Av La clinica 2520-310
Colonia Sertoma ,Mty N.L. México
CP 64710
Tel-Fax 52 81 83482940 y 52 81 81146053
Celular 8183094806
www.conapeme.org
www.pediatramendoza.com
enrique@pediatramendoza.com
emendozal@yahoo.com.mx
Webmaster: CONAPEME
Coordinador Nacional: Seminario Ciberpeds-Conapeme
Av La clinica 2520-310
Colonia Sertoma ,Mty N.L. México
CP 64710
Tel-Fax 52 81 83482940 y 52 81 81146053
Celular 8183094806
www.conapeme.org
www.pediatramendoza.com
enrique@pediatramendoza.com
emendozal@yahoo.com.mx
Decálogo de la Receta Electrónica
Somos Medicina
|
Posted: 17 May 2012 07:06 AM PDT
La implantación de la receta electrónica en España y sus 17 autonomías está siendo escalonada,heterogénea e ineficaz en muchos casos. En Estados Unidos, con un sistema sanitario eminentemente privado, los problemas que se prevén para la eReceta son mayores si cabe. Por ello el American College of Emergency Physiciansa querido poner sobre la mesa un decálogo para que la receta electrónica no sea una dificultad añadida.
Estas once medidas para la correcta implantación de la receta electrónica, muy aplicables también en nuestro entorno, evidencian que el sentido común muchas veces falla en la digitalización de procesos.
Esperemos que esta vez sí, se escuche a los usuarios (en este caso los médicos) sobrelas necesidades reales que tienen en la consulta. La receta electrónica tiene que venir a paliar los déficits y la burocracia que generan las recetas en papel. Si sólo conseguimos crear nuevos problemas la digitalización por si misma es un sinsentido.
Visto en el siempre interesante Primum non nocere de Rafa Bravo
|
martes, 15 de mayo de 2012
Pequeñas articulaciones, futuro de la artroscopia
sábado, 12 de mayo de 2012
Pequeñas articulaciones, futuro de la artroscopia - DiarioMedico.com
Pequeñas articulaciones, futuro de la artroscopia - DiarioMedico.com
LA DEGENERACIÓN TAMBIÉN SERÁ UNA PRÓXIMA CANDIDATA
Pequeñas articulaciones, futuro de la artroscopia
El abordaje de las pequeñas articulaciones por vía artroscópica empieza a ser una realidad clínica, así como las degeneraciones. El fenómeno es resultado del perfeccionamiento metodológico y de sus ventajas.
Enrique Mezquita | 11/05/2012 00:00
El XXX Congreso de la Asociación Española de Artroscopia (AEA), que concluye mañana en Valencia, reúne a 700 especialistas nacionales y extranjeros para analizar los últimos avances en este campo. En este escenario, los especialistas han señalado que las pequeñas articulaciones y la patología degenerativa son dos de los principales campos que marcan el futuro inmediato de la disciplina.
Según Eduardo Sánchez Alepuz, presidente del comité organizador, "nuestro campo abarca todas las articulaciones, grandes y pequeñas, y actualmente se pretende dar un impulso a las artroscopias menos frecuentes. Empezamos por rodilla, hombro y cadera (según datos de un estudio de hace tres años de la AEA, el 78 por ciento de artroscopias realizadas son de rodilla y el 17 por ciento, de hombro), pero existen otras articulaciones pequeñas (muñeca, dedos, codo o pie), donde estamos avanzando cada vez más".
Sitio específico
Además, ha señalado que, "al margen del paciente laboral y deportivo, que son los más subsidiarios de estas técnicas quirúrgicas, estamos intentando abrirnos a otro tipo de patología, la degenerativa". El especialista ha destacado que, a día de hoy, "la cirugía artroscópica ya tiene campo en este sentido". A modo de ejemplo, ha señalado el abordaje mediante esta técnica de una degeneración de muñeca-mano (rizartrosis), "que hace unos años se tendría que haber hecho inexorablemente mediante cirugía abierta".
También ha destacado su impacto en otra situaciones, como el caso de un chico joven con pinzamiento con signos degenerativos en la cadera. "Hace unos años era impensable abordarlo así y había que decirle a esa persona joven con dolores de cadera que debía esperar hasta que llegara el momento de ponerse una prótesis de cadera, con lo que ello supone de limitación funcional. En este sentido, ha recordado que "vivimos en una sociedad moderna y los pacientes tienen exigencias. Una cirugía mínimamente invasiva, que tiene como objetivo fundamental la pronta recuperación del paciente, puede satisfacerlas". Teniendo en cuenta que vivimos una época en que los costes "se miden y cuantifican, eso es muy importante".
La artroscopia es una cirugía mínimamente invasiva, poco dolorosa y de rápida recuperación empleada en el diagnóstico y tratamiento de las dolencias de las articulaciones (hombro, codo, muñeca, rodilla y cadera) y que permite diagnosticar el daño con precisión. Consiste en el empleo de un tubo de fibra óptica que se introduce en la zona dañada, acción que permite observar a través de una pantalla el interior de la cavidad articular y diagnosticar el daño con gran precisión.
Además, tiene la ventaja añadida de que disminuye la morbilidad, el dolor postoperatorio, las estancias hospitalarias, el tiempo de recuperación y el consiguiente absentismo laboral.
Actualmente se emplea frecuentemente en el tratamiento de las articulaciones y, de hecho, alrededor del 90 por ciento de las alteraciones que necesitan tratamiento quirúrgico se pueden abordar mediante esta técnica.
Según Eduardo Sánchez Alepuz, presidente del comité organizador, "nuestro campo abarca todas las articulaciones, grandes y pequeñas, y actualmente se pretende dar un impulso a las artroscopias menos frecuentes. Empezamos por rodilla, hombro y cadera (según datos de un estudio de hace tres años de la AEA, el 78 por ciento de artroscopias realizadas son de rodilla y el 17 por ciento, de hombro), pero existen otras articulaciones pequeñas (muñeca, dedos, codo o pie), donde estamos avanzando cada vez más".
Sitio específico
Además, ha señalado que, "al margen del paciente laboral y deportivo, que son los más subsidiarios de estas técnicas quirúrgicas, estamos intentando abrirnos a otro tipo de patología, la degenerativa". El especialista ha destacado que, a día de hoy, "la cirugía artroscópica ya tiene campo en este sentido". A modo de ejemplo, ha señalado el abordaje mediante esta técnica de una degeneración de muñeca-mano (rizartrosis), "que hace unos años se tendría que haber hecho inexorablemente mediante cirugía abierta".
También ha destacado su impacto en otra situaciones, como el caso de un chico joven con pinzamiento con signos degenerativos en la cadera. "Hace unos años era impensable abordarlo así y había que decirle a esa persona joven con dolores de cadera que debía esperar hasta que llegara el momento de ponerse una prótesis de cadera, con lo que ello supone de limitación funcional. En este sentido, ha recordado que "vivimos en una sociedad moderna y los pacientes tienen exigencias. Una cirugía mínimamente invasiva, que tiene como objetivo fundamental la pronta recuperación del paciente, puede satisfacerlas". Teniendo en cuenta que vivimos una época en que los costes "se miden y cuantifican, eso es muy importante".
La artroscopia es una cirugía mínimamente invasiva, poco dolorosa y de rápida recuperación empleada en el diagnóstico y tratamiento de las dolencias de las articulaciones (hombro, codo, muñeca, rodilla y cadera) y que permite diagnosticar el daño con precisión. Consiste en el empleo de un tubo de fibra óptica que se introduce en la zona dañada, acción que permite observar a través de una pantalla el interior de la cavidad articular y diagnosticar el daño con gran precisión.
Además, tiene la ventaja añadida de que disminuye la morbilidad, el dolor postoperatorio, las estancias hospitalarias, el tiempo de recuperación y el consiguiente absentismo laboral.
Actualmente se emplea frecuentemente en el tratamiento de las articulaciones y, de hecho, alrededor del 90 por ciento de las alteraciones que necesitan tratamiento quirúrgico se pueden abordar mediante esta técnica.
VISIÓN GLOBALIZADORA
Para transmitir los últimos avances y novedades en el campo de la artroscopia, el congreso que se celebra en Valencia presenta un programa científico ambicioso y muy variado, que incluye mesas de actualización, de expertos a debate y de videotécnicas, comunicaciones libres y cursos de instrucción, que se simultanean para que el asistente pueda elegir en todo momento la articulación y patología que más le interesa. Además, también alberga importantes cirugías en directo, realizadas desde el Centro de Rehabilitación y Recuperación de Levante (CRRL). Esta visión global es muy importante, sobre todo si se tiene en cuenta que en España se realizan aproximadamente 200.000 artroscopias cada año -15 millones en Europa y más de 20 millones en Estados Unidos-. Además, el impacto de la técnica es muy positivo a otros niveles, ya que ofrece grandes beneficios para el paciente y rentabilidad económica para la sociedad y las administraciones sanitarias.
Publicado por salud equitativa en 08:26
BECA PARA ENTRENAMIENTO EN NEURO Y CARDIO-ANESTESIA EN ROMA, ITALIA
Anestesiología y Medicina del Dolor se complace en comunicarle que la Confederación Latinoamericana de Sociedades de Anestesiología (CLASA)
ofrece becas para los anestesiólogos latinoamericanos miembros activos
de sus sociedades nacionales, interesados en neuro y cardioanestesia.
Para detalles sobre esta beca siga los enlaces que le enviamos o comuníquese con el Dr. Flavio Veintemilla Sig-Tu ( flaviovs@gu.pro.ec ) de la Comisión de Educación de CLASA, o puede consultar el portal de CLASA www.clasa-anestesia.org
BECA PARA ENTRENAMIENTO EN NEURO Y CARDIO-ANESTESIA EN ROMA, ITALIA |
Reglamento de Beca CLASA, Roma Italia. 2012
Formulario de Beca CLASA, Roma Italia. 2012
|
Atentamente
Anestesiología y Medicina del Dolor
Suscribirse a:
Entradas (Atom)